Part 7/8:
Investor Perspective: Stability Amidst Hiccups
Despite recent setbacks, Gilead remains a financially sound entity. With about $21 billion in cash reserves and generating impressive profits—approximately $4 billion per quarter—the perception of Gilead as struggling seems unfounded. Investors need to keep in mind the larger picture, which depicts Gilead as still deeply embedded in the hepatitis C market with substantial market share and potential for future growth.